StocksMedium•30 September 2026•
1 min read
Lantheus Receives CMS Transitional Pass-Through Status for PYLARIFY TruVu
Key Facts
1The Centers for Medicare & Medicaid Services (CMS) granted transitional pass-through status for Lantheus' PYLARIFY TruVu.
2A permanent HCPCS code will become effective on October 1, 2026, to support reimbursement and patient access.
The Centers for Medicare & Medicaid Services (CMS) granted transitional pass-through status for Lantheus' PYLARIFY TruVu. According to GlobeNewswire, a permanent HCPCS code will become effective on October 1, 2026, to support reimbursement and patient access for the imaging agent in clinical settings.
LNTH closed at $99.51 on September 29, 2026, after reaching a day high of $99.85 and a low of $99.31. This regulatory milestone is intended to ensure adequate reimbursement for the company's radiopharmaceutical product, facilitating its commercial availability and adoption in the medical imaging market.